Southern Launch puts finishing touches to space launch range

Rocket range operator Southern Launch is putting the finishing touches to Australia’s latest permanent spaceport ahead of its first launch. New launch facilities at the Koonibba Test Range north of Ceduna in outback South Australia are almost ready for the launch of German manufacturer HyImpulse’s SR75 rocket. The launch will will test HyImpulse’s hybrid propulsion…

GMG to build Graphene Aluminium Ion Battery pilot plant

Brisbane’s Graphene Manufacturing Group has secured Queensland government backing for a proposed Automated Battery Pilot Plant for the manufacture of GMG’s Graphene Aluminium Ion Battery. The company signed a Queensland Critical Minerals and Battery Technology Fund Agreement with the state for a grant of $2 million. GMG is using graphene to produce aluminium-ion batteries utilising…

GMG gets $2 million Queensland government grant for battery pilot plant

Graphene Manufacturing Group announced this week that it has signed a Queensland Critical Minerals and Battery Technology Fund Agreement with the state government for a $2 million grant, supporting the company’s proposed battery pilot plant. Brisbane-based and Toronto-listed GMG is commercialising graphene aluminium ion batteries among other graphene-based products.  GMG claims that their batteries, developed…

Climate change puts global semiconductor manufacturing at risk. Can the industry cope?

By Josh Lepawsky, Memorial University of Newfoundland Semiconductors are the basic building blocks of microchips. These technological marvels are in everything from lightbulbs and toothbrushes to cars, trains and planes, not to mention the vast array of electronics that have become integral to many people’s daily lives. The 21st century chip manufacturing industry has been…

Mesoblast gets FDA go ahead for pediatric drug

The US Food and Drug Administration has told biotechnology company Mesoblast that it now has sufficient clinical data to support a submission to approve the company’s remestemcel-L drug for treatment of pediatric patients. Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft versus host disease, and biologic-resistant inflammatory bowel…